Bisindolylmaleimide X

Bisindolylmaleimide X (Ro 31-8425, BIM-X) is a cell-penetrating PKC inhibitor. Bisindolylmaleimide X is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM. Bisindolylmaleimide X inhibits the proliferation of CD4 T cells in vitro. Bisindolylmaleimide X inhibits eNOS-Ser1177 phosphorylation in human embryonic vein endothelial cells. Bisindolylmaleimide X can be used for research on the immune system and cardiovascular diseases[1][2][3].

Product Specifications

CAS Number

[131848-97-0]

Product Name Alternative

BIM-X; Ro31-8425

UNSPSC

12352005

Hazard Statement

H301-H311-H331-H341

Target

CDK; PKC

Related Pathways

Cell Cycle/DNA Damage; Epigenetics; TGF-beta/Smad

Applications

COVID-19-anti-virus

Field of Research

Inflammation/Immunology; Cardiovascular Disease

Smiles

NCC1CCN2C(C1)=C(C3=C2C=CC=C3)C4=C(C5=CN(C)C6=CC=CC=C65)C(NC4=O)=O

Molecular Formula

C26H24N4O2

Molecular Weight

424.49

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P361-P403+P233-P405-P501

References & Citations

[1]Levy O, et al. A cell-based drug delivery platform for treating central nervous system inflammation. J Mol Med (Berl) . 2021 May;99 (5) :663-671.|[2]Song W, et al. Icariside II induces rapid phosphorylation of endothelial nitric oxide synthase via multiple signaling pathways. PeerJ. 2022 Oct 25;10:e14192. |[3]Brehmer D, et al. Proteome-wide identification of cellular targets affected by bisindolylmaleimide-type protein kinase C inhibitors. Mol Cell Proteomics. 2004 May;3 (5) :490-500.